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The magnitude of the suspected increase in risk of acute
interstitial nephritis among proton pump inhibitor users is
uncertain. Here, we conducted a nested case-control study
using routinely collected national health and drug dispensing
data in New Zealand to estimate the relative and absolute
risks of acute interstitial nephritis resulting in hospitalization
or death in users of proton pump inhibitors. The cohort
included 572,661 patients without a history of interstitial
nephritis or other renal diseases who started a new episode
of proton pump inhibitor use between 2005 and 2009. Cases
had a first diagnosis after cohort entry of acute interstitial
nephritis confirmed by hospital discharge letter or death
record, and renal histology (definite, 46 patients), or
discharge letter or death record only (probable, 26 patients).
Ten controls, matched by birth year and sex, were randomly
selected for each case. In the case-control analysis based on
definite cases and their controls, the unadjusted matched
odds ratio (95% confidence interval) for current versus past
use of proton pump inhibitors was 5.16 (2.21–12.05). The
estimate was similar when all cases (definite and probable)
and their corresponding controls were analyzed, and when
potential confounders were added to the models. The crude
incidence rates and confidence intervals per 100,000 person-
years were 11.98 (9.11–15.47) and 1.68 (0.91–2.86) for current
and past use, respectively. Thus, current use of a proton
pump inhibitor was associated with a significantly increased
risk of acute interstitial nephritis, relative to past use.
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Concern about a possible increased risk of acute interstitial
nephritis among omeprazole users was first raised in 1992.1
Subsequently, several published case reports and case
series suggested a class effect of proton pump inhibitors
(PPIs) (including omeprazole, pantoprazole, lansoprazole,
rabeprazole, and esomeprazole) on the occurrence of acute
interstitial nephritis.2–6 Anecdotal case reports received by
national drug safety authorities prompted regulators in
several countries to urge caution when prescribing PPIs7–12;
however, despite these warnings, several studies have shown
concerning and continuing levels of inappropriate prescri-
bing of PPIs in both hospital and primary care settings.13–16
Surprisingly, however, only one study has formally
explored the risk of acute interstitial nephritis in PPI users.
This study comparing the use of omeprazole on the index
date with nonuse reported an odds ratio of 3.20; however, the
diagnoses were not histologically validated and chance could
not be ruled out as a possible explanation (95% confidence
interval (95% CI) 0.80–12.79).17 Other research has suggested
that the absolute risk is very low, but has relied on
unsystematic case identification methods and imprecise
estimates of PPI exposure.9,18 We did a population-based
case-control study nested in a cohort of New Zealand
users of omeprazole, pantoprazole, or lansoprazole (the PPIs
available in New Zealand) to estimate the relative and
absolute risks of acute interstitial nephritis resulting in
hospitalization or death in current and recent users of these
drugs compared with past users.
RESULTS
From 1 January 2005 to 31 August 2009, the Ministry of
Health identified 794,230 patients from the Pharmaceutical
Collection who had been dispensed at least one course of PPI
treatment (Figure 1). The study cohort comprised 572,661
patients who had correctly linked health and dispensing data,
begun an episode of PPI use between 1 May 2005 and 31
August 2009, and did not have a history of renal disease
(including interstitial nephritis) before cohort entry. From
the study cohort, we identified 1164 patients as potential
cases. We excluded 529 patients whose additional diagnoses
indicated an infection of the kidney or urinary tract, and
requested hospital discharge letters, postmortem reports, and
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renal histology reports for the remaining 635 potentially
eligible cases, receiving information for 617 patients (97.2%).
On the basis of this information, an additional 545 patients
were excluded (most had pyelonephritis). The case-control
study therefore included 72 validated cases who presented
acutely with interstitial nephritis (46 definite, histologically
confirmed; 26 probable, discharge letter confirmed) and 719
matched controls (460 definite and 259 probable). There
were no fatal cases. Owing to a data management oversight,
only nine controls were selected for one case.
Table 1 shows the characteristics of the cases and controls.
Cases (definite and all) were more likely than controls to be
of European ethnicity, to be current users of drugs other than
PPIs associated with increased risk of acute interstitial
nephritis, to have been hospitalized in the previous year for
any reason, and to live in the most deprived socioeconomic
areas (Supplementary Table S1 online). Omeprazole was the
most commonly dispensed PPI at the last dispensing before
the index date, and almost two-thirds of cases and controls
who were current users were dispensed a ‘standard’ daily dose
at the last dispensing before the index date (Supplementary
Table S2 online).
The results of the main analysis are shown in Table 2. In
the matched analysis confined to definite cases and controls,
the unadjusted odds ratio was 5.16 (95% CI 2.21–12.05;
Po0.001) for current use of any study PPI compared with
Preliminary cohort of proton pump inhibitor
users identified by the Ministry of Health
(n=794,230)
Correctly linked data cohort
(n=791,512)
Patients with
incorrectly linked
data
(n=2718)
Excluded (n=218,851)
Cohort entry before
1 May 2005 (n=199,134)
History of renal disease
before cohort entry
(n=19,717)
Study cohort
(n=572,661)
Concurrent infection
diagnosis (n=529)
Potential cases (n=635)
(Discharge letters, post mortem reports and
renal histology reports requested)
Definite cases
(n=46)
Probable cases
(n=26)
Patients with provisional interstitial nephritis
diagnosis
(n=1164)
No provisional
interstitial nephritis
diagnosis
(n=571,497)
Excluded (n=563)
No/insufficient
information (n=18)
Not interstitial
nephritis† (n=530)
Interstitial nephritis
secondary to systemic
disease or
misdiagnosis‡§ (n=15)
*
Figure 1 | Study flow diagram. *The dashed line indicates that this part of the figure only describes the case identification process.
wDetermined after reviewing patients’ hospital discharge information. zChronic interstitial nephritis with early amyloid disease (n¼ 1); focal
segmental glomerulosclerosis (n¼ 1); glomerulonephritis (n¼ 1); light chain cast nephropathy (n¼ 3); minimal change disease with nephrotic
syndrome (n¼ 1); multiple myeloma (n¼ 2); systemic lupus erythematosus (n¼ 1); vasculitis (n¼ 1); acute tubular necrosis (n¼ 2); nonsteroidal
anti-inflammatory drug nephropathy in context of dehydration (n¼ 1); ‘interstitial nephritis on USS (ultrasound)’ (n¼ 1). yDetermined
after consultation with a renal physician.
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past use (all cases and controls odds ratio 4.82; 95% CI
2.43–9.58; Po0.001). Recent use was associated with elevated
risk; however, the findings were not significant. In secondary
analyses, we found no conclusive evidence of a dose-response
relationship or duration effect (Supplementary Tables S3 and
S4 online). Among patients who were only ever dispensed
omeprazole during the study period, the unadjusted matched
odds ratio for definite cases and controls was 4.00 (95% CI
1.70–9.42; P¼ 0.002) for current use compared with past use
(all cases and controls odds ratio 4.78; 95% CI 2.34–9.78;
Po0.001). Recent use was associated with a nonsignificant
increase in risk.
Adjusting for ethnicity, socioeconomic status, use of other
drugs associated with increased risk of interstitial nephritis in
the 30 days before the index date (including nonsteroidal
anti-inflammatory drugs and antibiotics), and hospital
admissions in the year before the index date for any reason,
including for specific conditions associated with renal disease
in general, had a negligible effect on the results of the primary
and secondary analyses.
Table 3 shows that the crude absolute risk of acute
interstitial nephritis per 100,000 person-years was substan-
tially higher for current users compared with past users
(11.98 vs. 1.68), and was intermediary in recent users (4.28).
The absolute risk for current users who were 60 years and
above was considerably higher than for younger current
Table 1 | Characteristics of cases and matched controls at index date
Definite All
Cases Controls Cases Controls
(n¼ 46) (n¼ 460) (n¼ 72) (n¼ 719)
Age (years) (mean (s.d.)) 65.4 (11.3) 65.4 (11.2) 64.7 (13.9) 64.7 (13.8)
Female (n (%)) 26 (56.5) 260 (56.5) 44 (61.1) 440 (61.2)
Ethnicitya (n (%))
European 43 (93.5) 370 (80.4) 63 (87.5) 582 (81.0)
Ma%ori 2 (4.4) 19 (4.1) 4 (5.6) 35 (4.9)
Pacific Island 1 (2.2) 9 (2.0) 2 (2.8) 18 (2.5)
Asian — 25 (5.4) 1 (1.4) 36 (5.0)
Other — 4 (0.9) — 4 (0.6)
Missing — 33 (7.2) 2 (2.8) 44 (6.1)
PPI type at last dispensing before the index date (n (%))
Omeprazoleb 41 (89.1) 419 (91.1) 65 (90.3) 652 (90.7)
Pantoprazole 4 (8.7) 39 (8.5) 6 (8.3) 62 (8.6)
Lansoprazole 1 (2.2) 2 (0.4) 1 (1.4) 5 (0.7)
Use of other drugs associated with increased interstitial nephritis risk in the 30 days before index datec,d (n (%))
Yes 26 (56.5) 190 (41.3) 42 (58.3) 289 (40.2)
Hospitalization in the year before the index date for any diagnosis (n (%))
Yes 23 (50.0) 136 (29.6) 36 (50.0) 214 (29.8)
Abbreviation: PPI, proton pump inhibitors.
aMultiple recorded ethnicities were categorized according to a prioritization algorithm developed by Statistics New Zealand: Ma%ori, Pacific Island, Asian, Other, European.
bIncludes patients dispensed Helicobacter pylori triple therapy, which consists of omeprazole and two antibiotics.
c10 cases (13.9%) and 40 controls (5.6%) had incomplete dispensing information because their index dates occurred o30 days after cohort entry.
dNonsteroidal anti-inflammatory drugs, other analgesics, aspirin and other anticoagulants, antibiotics and other antimicrobials, anxiolytics, anti-epileptics, diuretics,
ACE inhibitors, angiotensin II antagonists, beta-blockers, calcium channel blockers, H2 receptor antagonists, immune modulators and miscellaneous other drugs (see
Supplementary Table S9 online for a complete listing).
Table 2 | Risk of acute interstitial nephritis in users of the
proton pump inhibitors omeprazole, pantoprazole, or
lansoprazole
Cases Controls
Matched odds
ratio (95% CI) P-value
Definite casesa n¼ 46 n¼ 460
Current use 35 207 5.16 (2.21–12.05) o0.001
Recent use 4 56 2.38 (0.65–8.67) 0.188
Past use 7 197 1.0 —
All casesb n¼ 72 n¼ 719
Current use 55 332 4.82 (2.43–9.58) o0.001
Recent use 5 89 1.72 (0.57–5.22) 0.337
Past use 12 298 1.0 —
Abbreviation: CI, confidence interval.
aVerified by discharge letter and renal biopsy.
bDefinite and probable (verified by discharge letter only) cases.
Table 3 | Incidence rates for acute interstitial nephritis in
users of the proton pump inhibitors omeprazole,
pantoprazole, or lansoprazole
All
cases
Person-
years
Incidence rate (95% CI)
per 100,000 person-years
Entire study cohort n¼ 72
Current users 55 459 241 11.98 (9.11–15.47)
Recent users 5 116 735 4.28 (1.57–9.49)
Past users 12 714 116 1.68 (0.91–2.86)
Current users by age
(years) at cohort entry
n¼ 55
15–49a 3 135 421 2.22 (0.56–6.03)
50–59 9 101 278 8.89 (4.33–16.31)
60–69 19 99 575 19.08 (11.83–29.25)
70–79 15 73 476 20.41 (11.86–32.92)
80þ 9 40 488 22.23 (10.84–40.79)
Abbreviation: CI, confidence interval.
aThe youngest case was 17 years old.
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users; for instance, for every 100,000 PPI users in the 60 plus
age group, about 20 per year developed acute interstitial
nephritis as compared with 2 per year in those aged 15–49
years.
DISCUSSION
We found that the current use of the PPIs omeprazole,
pantoprazole, or lansoprazole was associated with a sig-
nificantly increased risk of acute interstitial nephritis
resulting in hospitalization compared with past use. The
absolute risks were very low, but appeared substantially
higher in older users. Although these rates should be
interpreted with some caution owing to small numbers and
wide CIs, the apparent age-related effect has clinically
important implications given the aging population and the
higher proportionate use of PPIs in older patients (using
population data from the 2006 Census19 we estimated that
about 31% of the New Zealand population aged 60 years or
more was dispensed a PPI at least once between 1 January
2005 and 31 August 2009, as compared with 12% in those
aged 15–49 years). PPIs were also used by children, including
B4% of New Zealand infants per year.
We searched MEDLINE up to October 2013 to find
analytical epidemiological studies that investigated PPIs and
the risk of interstitial nephritis. A case-control study using
data from the United Kingdom General Practice Research
Database (based on only five exposed, nonvalidated, cases)
found an odds ratio of 3.20 (95% CI 0.80–12.79) when
comparing the use of omeprazole on the index date with its
nonuse.17 Moreover, the strength of the association may have
been underestimated because the cohort included a mix of
new and long-term users (although we found no evidence of
a duration effect), and the reference category included both
past and never users. A recent United States study based
on information from a private insurance database reported
a significant relationship between PPI use and acute
kidney injury (odds ratio 1.72; 95% CI 1.27–2.32;
Po0.001); however, there was considerable potential for
misclassification of exposure, the cases were not validated,
and only 3 of the 854 cases had an interstitial nephritis
diagnostic code.20 We found only one published account of
absolute risk, which used cases reported to the authors and
estimated dispensing information from PPI distributors in
the Auckland area of New Zealand. The authors found an
incidence similar to ours of 8.0 per 100,000 person-years
(95% CI 2.6–18.7) based on 15 cases and an estimated
750,000 1-month treatments dispensed annually.18 In
addition, two cases of interstitial nephritis from a cohort of
22,050 first-time omeprazole users were reported in the 1990s
as part of a prescription event monitoring program in New
Zealand.9 Although both studies actively searched for cases,
the systematic identification of cases used in the present
research likely resulted in more complete case ascertainment,
whereas the use of detailed dispensing information allowed
for more accurate estimates of person-years at risk for each
exposure category. Our study also provides more clinically
useful information by estimating the incidence of acute
interstitial nephritis in past users to compare with the
incidence in current and recent users.
Our study has a number of additional strengths compared
with previous research. We minimized selection bias by using
routinely collected health and dispensing data for an entire
country where there is universal access to the health-care
system. This information is likely to be accurate, complete,
and consistent owing to national clinical coding standards for
recording hospital discharge and mortality information, and a
pharmaceutical claims system that reimburses pharmacists
only if key dispensing details are provided. Our case definition
only included patients whose interstitial nephritis was severe
enough to cause hospitalization or death (although no fatal
cases were found), minimizing the possibility that current
users of PPIs were more likely to be referred and diagnosed
because doctors were aware of a possible link between PPI use
and acute interstitial nephritis (referral and diagnostic bias).
In addition to using a broad search strategy in the preliminary
identification of potential cases, we verified diagnoses with
clinical information. Although renal histology is the only way
to definitively diagnose acute interstitial nephritis, we also
collected information on patients without histological con-
firmation, as biopsy referral patterns may differ by treating
clinician or patient age. The findings were similar when
considering histologically confirmed (definite) cases and all
cases. We also likely identified virtually all users of the study
PPIs. These drugs were available only by prescription during
the study period, and a very high proportion of PPI
dispensing records included National Health Index numbers,
unique patient identifiers, which allowed us to link dispensing
and health data (90% in 2005, increasing to 98% in 2009). In
addition, we compared the risk of acute interstitial nephritis
in similar groups of users by restricting cohort eligibility to
patients who initiated a new episode of PPI use during the
study period. Because of the incomplete National Health
Index coverage in the earlier period of the study, it is possible
that some long-term users may have been included in the
study cohort, although they would comprise a very small
proportion. We also determined exposure on the basis of
dispensing data, and not on prescription data. Although
it is impossible to know whether patients actually took
their medicines as prescribed, any non-adherence would
likely be similar between cases and controls and would result
in an underestimation of effects.
Confounding by age, sex, concomitant drug use (includ-
ing nonsteroidal anti-inflammatory drugs and antibiotics), or
other medical conditions is unlikely to explain the key
findings. Cases and controls were matched by birth year and
sex, and we excluded patients with a recorded history of
kidney disease before cohort entry. Confounding by indica-
tion should have been avoided as all study members were
prescribed a PPI at some time during the study period.
Potential confounding by other subsidized prescription
medicines possibly associated with interstitial nephritis, or
non-renal medical conditions associated with increased risk
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of renal disease in general, was explored in the analysis with
little effect on the results. However, we did not have
information about unsubsidized or over-the-counter drugs
(which are not recorded in the Pharmaceutical Collection),
diagnoses made in primary care, or lifestyle factors such as
smoking and obesity. Although aspirin and several nonster-
oidal anti-inflammatory drugs were available over-the-
counter throughout the study period, we expected that most
chronic users of these drugs would be obtaining them by
subsidized prescription owing to financial considerations. We
were able to partially account for diagnoses made in primary
care through analyzing the dispensing data, and found that
adjustment for a range of medicines usually prescribed for
conditions such as hypertension, diabetes, or congestive heart
failure did not affect the estimates. Although we lacked
important lifestyle information, the lower bound of the CI
for current users was so large that a single unmeasured
confounder would have to exert a large effect to nullify our
results.
Our study had several limitations, including a relatively
small number of identified cases, which affected the precision
of the findings as shown by the wide CIs. However, our cases
represent the largest series to be published to date, and the
detailed dispensing data available for the entire study cohort
enabled more precise estimates of absolute risk than previous
studies. We were limited by the unavailability of electronic
records before 1988, which meant that we did not have full
lifetime hospitalization data for most people in the study
cohort. Although considerable care was taken to exclude
patients with previous interstitial nephritis or other renal
disease from the study cohort, the inadvertent inclusion of
any non-incident cases may have led to a slight over-
estimation of the association, assuming the recurrent episode
of interstitial nephritis occurred while the patient was
currently taking the PPI.
In conclusion, this study contributes to a growing body of
evidence suggesting that current users of PPIs are at an
increased risk of developing acute interstitial nephritis, and is
the first study to take a systematic approach to estimating
absolute risks. Although PPIs have revolutionized the care of
patients diagnosed with gastric acid–related disorders, these
drugs are not without risks. Greater caution is warranted
considering the extremely large number of patients using
these drugs, evidence of widespread inappropriate use, and
over-the-counter availability of these medicines in many
countries, including the United States and the United
Kingdom.
MATERIALS AND METHODS
Data sources
We used routinely collected information from New Zealand’s
National Minimum Dataset (hospital discharges from 1988)21 and
Mortality Collection (all hospital and community deaths).22
Diagnoses in these data sets were recorded using the International
Classification of Diseases 9th and 10th revision, Australian
Modification codes (ICD-9-AM, ICD-10-AM). We also used
information on dispensed drugs held in the Pharmaceutical
Collection,23 which records pharmacist dispensing claims for all
publicly funded prescription medicines in New Zealand. Patient
information in these data sets was linked using National Health
Index numbers, unique identifiers assigned to B98% of the New
Zealand population.24 The study was approved by the New Zealand
Multi-region Ethics Committee (MEC/11/EXP/098).
Identification of study cohort
All patients who were dispensed a study PPI (including users of
Helicobacter pylori triple therapy) at least once between 1 January
2005 and 31 August 2009 were identified from the Pharmaceutical
Collection by the Ministry of Health. The Ministry used the
National Health Index numbers of these patients to link their
dispensing and health information, providing us with the patients’
demographic data, details of all dispensings of the study PPIs and all
other medicines from 2005 to 2009, hospital admission details from
1988, and, where applicable, death details. Unique patient identifiers
were provided in lieu of National Health Index numbers for all
patients except those identified by the Ministry as potential cases
(see below). Cohort entry was the date of the first dispensing of a
study PPI between 1 January 2005 and 31 August 2009.
We excluded linked records in which the dispensing and health
information obviously could not have referred to the same person
(e.g., patients who supposedly received medicines before their
recorded birth date). To ensure that the study cohort included only
those patients who initiated a new episode of PPI use during the
study period (first-time users and those restarting after a break), we
excluded all patients who were dispensed a study PPI between
1 January 2005 and 30 April 2005 (New Zealand allows a maximum
90-day dispensed supply of a PPI at one time). We also excluded
patients with a recorded history of interstitial nephritis or other
renal diseases before their cohort entry date (Supplementary Tables
S5 and S6 online).
Identification of cases and controls
We asked the Ministry to identify all patients who were potentially
diagnosed with acute interstitial nephritis after cohort entry by
searching the hospital discharge and mortality data using the ICD-
10-AM rubrics (determined in consultation with a professional
clinical coder) under which interstitial nephritis may be coded (N10,
N118, N119, N12, N141, N142, and N144). As mortality informa-
tion for patients who died in 2009 had not yet been coded,
we searched the free text causes of death for these patients for
‘interstitial nephritis’. Next, we devised an algorithm to exclude
patients whose additional diagnoses indicated an infection of the
kidney or urinary tract (Supplementary Tables S7 and S8 online).
Finally, to verify the diagnoses of the remaining potential cases,
hospital discharge letters, postmortem reports, and any renal
histology reports were requested and independently reviewed by
M-LB and LP who were blinded to the patients’ PPI exposure status.
In cases where there was some uncertainty about a patient’s
diagnosis (17 cases) a renal physician was consulted, and patients in
whom interstitial nephritis was secondary to a systemic disease, or
who were misdiagnosed, were excluded. Definite cases were patients
who presented acutely with interstitial nephritis that was verified by
discharge letter or death record, and renal histology. Probable cases
were patients with only discharge letter or death record confirma-
tion. The diagnosis date was taken as the index date for each case
and their matched controls. We used risk set sampling25 from the
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study cohort to randomly select 10 controls (blinded to PPI
exposure status) for each case, matched by birth year and sex; hence,
controls were members of the study cohort who were at risk of
developing acute interstitial nephritis on the index date.
PPI use
Cases and controls. Cases and controls were defined as current
users of PPIs if their dispensed supply extended into the 30-day
period before the index date, recent users if their supply extended to
within 31–90 days before the index date, and past users if their
supply terminated 490 days before the index date. Because they
shared the same index date, the PPI exposure status of each case and
their matched controls was therefore determined at the same
calendar time.
Person-years of exposure in the study cohort. Person-years at
risk for current users, regardless of PPI type or total daily dose, were
determined by summarizing the dispensing data provided by the
Ministry into continuous episodes of use (defined as a series of
dispensings in which there was no more than a 30-day gap between
the end of one dispensed supply and the start of the next). Episodes
of current use were censored if the patient died, reached the end of
the study period, or if a case was diagnosed with acute interstitial
nephritis. The durations of all episodes were summed to determine
the total person-years of current use for the study cohort. For
patients who stopped taking a PPI, we estimated person-years of
follow-up in recent users by adding the amount of time occurring
31–90 days after the end of each continuous episode (59 days
maximum). Similarly, person-years of follow-up in past users were
determined by adding the amount of time occurring 91 or more
days after the end of each continuous episode. Follow-up in recent
and past users was censored if a new episode was started, the patient
died or reached the end of the study period, or if a case was
diagnosed with acute interstitial nephritis. The durations of follow-
up in recent and past users were, respectively, added together to give
the total recent and past person-years for the entire study cohort.
Current
Current
Current
30 days 59 days
Recent
Recent Past
Maximum 59 days30 days
Cohort
entry
date
Cohort
entry
date
Cohort
entry
date
End of
dispensed
supply
End of
dispensed
supply
End of
dispensed
supply
Maximum
30 days
Current use censored at earliest of:
a) death; b) end of study period;
c) diagnosed with acute interstitial nephritis
(if case)
Censored at earliest of:
a) start of new episode; b) death;
c) end of study period;
d) diagnosed with acute interstitial nephritis
(if case)
Censored at earliest of:
a) start of new episode; b) death;
c) end of study period;
d) diagnosed with acute interstitial nephritis
(if case)
a
b
c
Figure 2 |Determination of current, recent, and past person-years. (a) Patients who only contributed current person-years. (b) Patients who
contributed current and recent person-years. (c) Patients who contributed current, recent, and past person-years.
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According to our definitions, some patients only contributed
current person-years, some current and recent person-years, and
some current, recent, and past person-years (Figure 2).
Potential confounding factors
In addition to birth year and sex, we assessed information on the
following potential confounders: ethnicity; socioeconomic status;
use of other drugs in the 30 days before the index date, which are
associated with increased risk of interstitial nephritis (including
nonsteroidal anti-inflammatory drugs and antibiotics Supple-
mentary Table S9 online); and hospital admissions in the year
before the index date for any reason, and for specific conditions
associated with increased risk of renal disease in general (athero-
sclerosis, hyperlipidemia, hypertension, congestive heart failure,
Type I and Type II diabetes, hyperglycemia, cancer, hepatitis C, and
HIV/AIDS).
Statistical analysis
Conditional logistic regression was used to estimate odds ratios and
95% CIs. We estimated the risk of acute interstitial nephritis
resulting in hospitalization or death in definite cases and their
controls, and then in all (definite and probable) cases and controls.
The primary analysis explored the risk of acute interstitial nephritis
in current and recent users, respectively, of the study PPIs, with past
users as the reference group. In secondary analyses, we explored the
risk of acute interstitial nephritis according to duration of use
(p180 days,4180 days) in the subset of users who had taken PPIs
continuously between cohort entry and the index date (patients who
discontinued PPI use during the study period were excluded from
this analysis), investigated the impact of total daily dose (low,
standard, and high) taken by current users of any PPI, and examined
the risk in the subset of cases and controls who were only ever
dispensed omeprazole. Confounding was tested by entering the
potential confounders one at a time into the conditional logistic
regression model and the 10% change in estimate convention26 was
used to identify confounders.
Crude incidence rates in current, recent, and past users and age-
stratified rates in current users were calculated using the cohort data
by dividing the total number of cases in a particular exposure
category by that category’s person-years of follow-up. The Poisson
distribution was used to determine 95% CIs. Stata version 12 was
used for all analyses.
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Table S7. International Classification of Diseases 10th revision
Australian Modification codes (ICD-10-AM) that were used to identify,
and then exclude, potential cases who had a kidney or urinary tract
infection (patients concurrently diagnosed with N10 or N12 and any
of the ICD-10-AM codes listed in the table were excluded, regardless
of whether other ICD-10-AM codes were listed).
Table S8. International Classification of Diseases 10th revision
Australian Modification codes (ICD-10-AM) that were used to identify,
and then exclude, potential cases who had a kidney or urinary tract
infection and had not already been excluded according to Table S7
(patients concurrently diagnosed with N10 or N12 and any of the
ICD-10-AM codes listed in the table were excluded, provided there
were no other ICD-10-AM codes listed).
Table S9. Government-subsidized prescription drugs listed in the
New Zealand formulary known or suspected of increasing the risk of
interstitial nephritis, by therapeutic class.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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